Back to top

Bull of the Day

We upgrade our recommendation for Thoratec Corporation (THOR) to Outperform. HeartMate II units rose 22% in the six months ending June 30, 2012 wrapping up a robust half-year. Its competitor, HeartWare, has filed a PMA for a similar device which is not expected to be launched until 2015.

We believe that products such as HeartMate II will account for the major part of growth in the Ventricular Assist Device (VAD) market. Also, the company continues to do well in overseas markets despite economic turmoil in Europe.

The company recently raised guidance for 2012 following its results in the second quarter. We upgrade our recommendation on the stock with a price target of $44.00, based on a P/E of 29.3x our 2012 EPS estimate.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 2.99 +2.75%
CTPARTNERS… CTP 16.20 +2.02%
CHINA BIOLO… CBPO 46.93 +1.88%
THE PANTRY… PTRY 20.93 +1.65%
PIPER JAFFR… PJC 54.47 +1.57%